Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Functional consequence of MDR1 expression on imatinib intracellular concentrations.

Literature DB >> 12869489

Functional consequence of MDR1 expression on imatinib intracellular concentrations.

Nicolas Widmer, Sara Colombo, Thierry Buclin, Laurent A Decosterd.

Abstract

Entities: Chemical Gene

Mesh：

Substances：

Year: 2003 PMID： 12869489 DOI： 10.1182/blood-2003-03-0993

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

Keyword Cloud
Cited

× No keyword cloud information.

14 in total

1. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.

Authors: N Widmer; L A Decosterd; C Csajka; S Leyvraz; M A Duchosal; A Rosselet; B Rochat; C B Eap; H Henry; J Biollaz; T Buclin
Journal: Br J Clin Pharmacol Date: 2006-07 Impact factor: 4.335

2. Characterization of a multidrug-resistant chronic myeloid leukemia cell line presenting multiple resistance mechanisms.

Authors: Nathalia Daflon-Yunes; Flavio Eduardo Pinto-Silva; Raphael Silveira Vidal; Bruna Fortunato Novis; Tandressa Berguetti; Raphael Rodrigues Soares Lopes; Carla Polycarpo; Vivian M Rumjanek
Journal: Mol Cell Biochem Date: 2013-07-23 Impact factor: 3.396

3. The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment.

Authors: L N Eadie; P Dang; V A Saunders; D T Yeung; M P Osborn; A P Grigg; T P Hughes; D L White
Journal: Leukemia Date: 2016-06-24 Impact factor: 11.528

4. Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib.

Authors: Charles Chuah; Junia V Melo
Journal: Onco Targets Ther Date: 2009-02-18 Impact factor: 4.147

5. ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis.

Authors: Q Zheng; H Wu; Q Yu; D H Dennis Kim; J H Lipton; S Angelini; S Soverini; D Vivona; N Takahashi; J Cao
Journal: Pharmacogenomics J Date: 2014-09-23 Impact factor: 3.550

6. Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells.

Authors: Chie Hirayama; Hiroshi Watanabe; Reiko Nakashima; Takeru Nanbu; Akinobu Hamada; Akihiko Kuniyasu; Hitoshi Nakayama; Tatsuya Kawaguchi; Hideyuki Saito
Journal: Pharm Res Date: 2007-10-13 Impact factor: 4.200

Functional consequence of MDR1 expression on imatinib intracellular concentrations.

1. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.

2. Characterization of a multidrug-resistant chronic myeloid leukemia cell line presenting multiple resistance mechanisms.

3. The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment.

4. Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib.

5. ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis.

6. Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells.

Review 7. Predicting the response of CML patients to tyrosine kinase inhibitor therapy.

Review 8. Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer.

9. Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells.

10. N-alkylated isatins evade P-gp mediated efflux and retain potency in MDR cancer cell lines.